Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

Delayed Quote. Delayed  - 08/23 10:01:07 pm
119.44 USD   +0.26%
08/22 FOR U.S. MEDIA : Janssen Announces 25 Presentations at Upcoming ESC..
08/21 JOHNSON & JOHNS : With B.good, healthy eating comes to King of Pruss..
08/21 JOHNSON & JOHNS : Going from big pharma to farm-fresh
News SummaryMost relevantAll newsSector news 

Johnson & Johnson : J&J Cancer Drug Zytiga Now Backed For Publicly Funded Use In UK

share with twitter share with LinkedIn share with facebook
share via e-mail
05/16/2012 | 11:11am CEST

The U.K.'s health-care cost-effectiveness regulator Wednesday reversed an earlier decision and approved the publicly funded use of Johnson & Johnson's (JNJ) prostate-cancer pill Zytiga, after the U.S. company cut its price further.

Also known as abiraterone, Zytiga removes the prostate cancer tumor's supply of testosterone, preventing it from growing further and potentially extending a patient's life by more than three months. The medicine was rejected for use in the U.K. in February on grounds its terms of use wouldn't offer value for money.

Andrew Dillon, chief executive of the U.K.'s National Institute for Health and Clinical Excellence, or NICE, Wednesday said the manufacturer subsequently submitted fresh information, including a revised patient access scheme containing a deeper price discount to the National Health Service and more information about which patients would most benefit from its use and how many patients could receive the drug.

"These factors enabled the committee to revise its preliminary recommendation and now recommend the drug for use on the NHS," Dillon said in a statement. "It is an effective treatment, potentially extending life by more than three months, and it also allows patients to be treated at home as it can be taken orally."

Abiraterone costs GBP2,930 for a 30-day supply of 120 tablets. NICE didn't specify the size of the price cut offered by Johnson & Johnson.

Zytiga was approved by U.S. and European drug regulators last year. It is set to generate peak-year sales of $910 million.

-By Sten Stovall, Dow Jones Newswires; +44 207 842 9292; sten.stovall@dowjones.com

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on JOHNSON & JOHNSON
08/22 FOR U.S. MEDIA ONLY : Janssen Announces 25 Presentations at Upcoming ESC Congres..
08/21 JOHNSON & JOHNSON : With B.good, healthy eating comes to King of Prussia
08/21 JOHNSON & JOHNSON : Going from big pharma to farm-fresh
08/19 JOHNSON & JOHNSON : Diabetes Selfcare Demands Retail, Health Care Collaboration ..
08/19 JOHNSON & JOHNSON : ex-dividend day
08/18 JOHNSON & JOHNSON : Janssen Submits Application to U.S. FDA to Expand Indication..
08/18 JOHNSON & JOHNSON : Frost & Sullivan MindXChange Reveals How Organizations Can L..
08/18 JOHNSON & JOHNSON : Announces Ruling Related to REMICADE in the District of Mass..
08/18 JOHNSON & JOHNSON : Patanjali enters babycare segment
08/17 JOHNSON & JOHNSON : Patent for J&J's Remicade invalidated, cheaper version looms
More news
Sector news : Pharmaceuticals - NEC
10:32aDJASTRAZENECA : Sells Part of its Antibiotics Business to Pfizer -- Update
10:15aDJASTRAZENECA : Sells Part of Antibiotics Business to Pfizer
09:48a ASTRAZENECA : Pfizer to buy antibiotics business from AstraZeneca
09:03aDJASTRAZENECA : Sells Part of Antibiotics Business to Pfizer for Up to $1.575 Bill..
08/23DJU.S. Lawmakers Plan Hearing Over Wave of Agriculture Mergers
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
02:20a Looking At Top 5 Stocks In S&P 500 - Market Cap / Earnings Weight Influence O..
08/23 Who's Next After Medivation?
08/23 Janssen submits application in Europe for expanded use of Darzalex
08/23 HORMEL FOODS : A Dividend King With 50 Years Of Dividend Increases (Part 18 Of 1..
08/22 Tokai Pharma in flux with lead product candidate galeterone, enrollment in mi..
Financials ($)
Sales 2016 72 068 M
EBIT 2016 21 808 M
Net income 2016 16 515 M
Finance 2016 13 074 M
Yield 2016 2,62%
P/E ratio 2016 20,33
P/E ratio 2017 17,96
EV / Sales 2016 4,35x
EV / Sales 2017 4,06x
Capitalization 326 773 M
More Financials
Duration : Period :
Johnson & Johnson Technical Analysis Chart | JNJ | US4781601046 | 4-Traders
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 127 $
Spread / Average Target 6,1%
Consensus details
EPS Revisions
More Estimates Revisions
Alex Gorsky Chairman & Chief Executive Officer
Dominic J. Caruso Chief Financial Officer & Vice President
Paulus Stoffels Chief Scientific Officer
Susan L. Lindquist Independent Director
Charles O. Prince Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON16.28%326 773
ROCHE HOLDING LTD.-12.26%219 257
NOVARTIS AG-9.97%214 603
PFIZER INC.8.71%212 844
MERCK & CO., INC.20.37%175 812
More Results